Organ-specific bleeding patterns of anticoagulant therapy: lessons from clinical trials
|
|
- Rosa White
- 6 years ago
- Views:
Transcription
1 918 Theme Issue Article Organ-specific bleeding patterns of anticoagulant therapy: lessons from clinical trials Thomas Vanassche; Jack Hirsh; John W. Eikelboom; Jeffrey S. Ginsberg Population Health Research Institute, Thrombosis and Atherosclerosis Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada Summary Anticoagulants are effective at preventing and treating thrombosis, but can cause bleeding. For decades, vitamin K antagonists (VKAs) have been the only available oral anticoagulants. The development of non-vka oral anticoagulants (NOACs), which inhibit either factor Xa or thrombin stoichiometrically, has provided alternatives to VKAs for several indications. The results of recent large-scale randomised controlled trials comparing NOACs with VKAs for the prevention of stroke in patients with non-valvular atrial fibrillation (AF) have produced some unexpected results. As a group, NOACs showed similar efficacy as warfarin, but a reduced risk of major bleeding. The reduction in bleeding with NOACs was greatest with intracranial hemorrhage. In contrast, the relative risk of gastro-intestinal bleeding was increased with some NOACs. In this review, we explore the potential mechanisms as well as the implications of these organ-specific bleeding patterns. Keywords Venous thrombosis, stroke prevention, thrombosis Correspondence to: John Eikelboom 237 Barton Street East Hamilton, ON, L9K 1H8, Canada Tel.: ext 40323, Fax: eikelbj@mcmaster.ca Received: April 11, 2014 Accepted after major revision: July 10, 2014 Epub ahead of print: September 4, Thromb Haemost 2014; 112: Introduction Anticoagulants are effective for the prevention and treatment of thrombosis, but since they act by either reducing thrombin generation or inhibiting thrombin activity, they are associated with bleeding. The normal generation of thrombin at sites of vascular injury both reduces post-traumatic bleeding and prevents subclinical micro-bleeds from enlarging and forming clinically relevant bleeds. Both categories of bleeds are increased by anticoagulants. In the late 1980s and 1990s, several randomised controlled trials (RCTs) demonstrated that vitamin K antagonists (VKAs) in doses adjusted to target an international normalised ratio (INR) between 2.0 and 3.0 were effective in reducing the risk of cardiogenic embolism, primarily embolic strokes, in patients with nonvalvular atrial fibrillation (AF) (1). These trials showed consistent risk reductions of about two-thirds in the incidence of stroke with VKAs compared to no treatment in intention-to treat populations, and of about % in patients with excellent INR control. VKAs doubled the risk of major bleeding, but the trials had insufficient numbers of events to identify organ-specific patterns of bleeding (2). Although VKAs are effective in reducing stroke risk in patients with AF, they require routine laboratory monitoring (3). To obviate the need for monitoring, a new generation of non-vka oral anticoagulants (NOACs) with fewer drug and food interactions and more predictable pharmacokinetics has been evaluated. Over the past five years, several direct inhibitors of factor Xa or factor IIa (thrombin) have been evaluated in large RCTs (2, 4 8). Together, these trials enrolled more than 80,000 patients and to date (August, 2014), three compounds have been approved by regulatory authorities for prevention of stroke and systemic embolism in patients with non-valvular AF: two factor Xa inhibitors rivaroxaban and apixaban, and one thrombin inhibitor dabigatran. A fourth compound, the factor Xa inhibitor edoxaban, has recently been evaluated in a large RCT and could be approved shortly. In each of the recent trials, a NOAC was compared with aspirin or a VKA and each trial showed impressive efficacy and bleeding results for the NOAC (2, 4 8). Although these favourable results are likely, in part, due to careful selection of drug dose regimens, the greater variability of anticoagulant response to warfarin is also important; there were similar bleeding rates in NOAC- and warfarintreated patients in centres with good INR control (9, 10). Although major bleeding rates in the AF trials were low, the number of patients included in the trials was large, thereby providing a large absolute number of bleeding events. Further analysis revealed unexpected patterns of organ-related bleeding. In this paper, we summarise the relative risks of bleeding with NOACs compared with VKAs in different organs and explore possible mechanisms for the unexpected findings. Organ-specific patterns of bleeding Pooled data from the four trials comparing NOACs with VKAs (84,540 patients and 4,781 bleeding events) indicate that NOACs Thrombosis and Haemostasis 112.5/2014 Schattauer 2014
2 Vanassche et al. Organ-specific bleeding patterns in anticoagulation 919 were associated with a 23 % reduction in the relative risk (RR) of major bleeding (RR 0.77, 95 % confidence interval [CI] ) ( Figure 1 A). Further analysis of the overall major bleeding rates revealed two contrasting organ-specific bleeding patterns ( Figure 1 B). First, intracranial haemorrhage (ICH) was uniformly reduced by NOACs, with median relative risk reduction of about 60 % (median RR 0.42, range ). This large effect is very important, as ICH is associated with a mortality rate of up to 40 % and a high risk of permanent neurological deficits in survivors. Second, the effect on gastro-intestinal (GI) bleeding varied by NOAC compared with VKAs; rivaroxaban and the higher doses of dabigatran (150 mg bid) and edoxaban (60 mg od) increased the risk, apixaban and the lower dose of dabigatran (110 mg bid) produced a similar risk, and the lower dose of edoxaban (30 mg od) reduced the risk of GI bleeding. Potential causes of the patterns of organ specific bleeding Intracranial bleeding Although the quality of INR control (lower time in therapeutic range, TTR) is a risk factor for warfarin-associated bleeding (11, 12), most major bleeds, including ICH, occur while patients are within therapeutic range. In a recent study of 260 warfarin-associated cases of ICH, the majority of patients (78 %) presented with INR results of , while only 13.5 % had INR results higher than 3.0 (13). Furthermore, NOACs compared with warfarin were associated with a lower relative risk of ICH in centres with optimal INR control as well as in those with poor INR control (14), whereas a reduction in the relative risk of major bleeding was most evident in centers with poor INR control (9). These finding support the hypothesis that additional mechanisms, other than quality of INR control, are responsible for the large and consistent reductions in the risk of ICH with NOACs compared with VKAs. We propose two such mechanisms: 1) the A Figure 1: Overall and organ-specific relative risks of bleeding. Mean relative bleeding risk and 95 % confidence interval for all major bleeding (A) and by bleeding subtype (Gastrointestinal, haemorrhagic stroke, or other, B). Horizontal bars represent 95 % confidence interval of the pooled data. B Schattauer 2014 Thrombosis and Haemostasis 112.5/2014
3 920 Vanassche et al. Organ-specific bleeding patterns in anticoagulation different mechanisms of action of NOACs and VKAs; and 2) the unique physiology of the brain. Drug-related factors When a blood vessel wall is disrupted, blood comes into contact with tissue factor (TF), which activates coagulation, ultimately leading to formation of a thrombus or a haemostatic plug. By interfering with vitamin K metabolism, VKAs lower blood concentrations of four vitamin K dependent clotting factors (II, VII, IX, and X) (15), thereby effectively damping down thrombin generation following tissue injury. NOACs are stoichiometric inhibitors that selectively target the individual coagulation proteins, factor Xa (rivaroxaban, apixaban, edoxaban) and factor IIa (dabigatran). At concentrations seen with clinical use, stoichiometric inhibitors might be less effective than VKAs at blocking the high local concentrations of factor Xa or factor IIa generated in response to intense TF-mediated coagulation activation. TF is exposed to flowing blood at sites of rupture of a cerebral blood vessel ( Figure 2). The factor Xa or IIa molecules that escape neutralization are then able to generate more thrombin locally and limit the extent of bleeding, preventing it from becoming clinically overt (16). Brain-specific regulation of haemostasis The endothelial lining of brain capillaries is surrounded by pericytes and astrocytes, which produce a specialised subendothelial basal membrane that is rich in TF (17). It has been proposed that this TF-rich basal membrane acts as a protective mechanism against spontaneous intracerebral haematoma formation (18). Potentially further limiting the risk of bleeding is the low expression of tissue factor pathway inhibitor (TFPI) in the brain (18). Autopsy and imaging studies have shown that asymptomatic capillary brain bleeds are found in 5 10 % of persons over the age of 60 in the general population. The prevalence of these microbleeds increases with age (19), as do other risk factors typically associated with ICH, such as hypertension and amyloid angiopathy. By impairing physiological haemostasis, anticoagulant therapy could promote the transformation of a subclinical micro-bleed into a clinically apparent macro-bleed, a notion that is supported Table 1: Gastrointestinal effects of warfarin and direct acting oral anticoagulants. Warfarin Dabigatran Rivaroxaban Apixaban Edoxaban Bioavailability % 7 % 66 % 50 % 62 % Active drug in the gut? No (prodrug, activated by gut esterases) Intraluminal levels of active drugs < 5 % (inactive) ~ 80 % (28) ~ 30 % (30) ~35 % (29) ~50 % (27) by the observation that the presence of cerebral micro-bleeds markedly increases the risk of intracerebral haemorrhage in VKAtreated patients (20, 21). We propose that NOACs are associated with lower frequencies of ICH than VKAs, because the two proposed mechanisms act in consort. Thus, the effects of the stoichiometric inhibitors can be overwhelmed by high concentrations of their target clotting enzymes and high concentrations of these clotting enzymes are generated locally by the high concentration of TF in the cerebrovascular micro-circulation. Our hypothesis is supported by results of several animal studies. In a murine model of induced intracerebral haematoma, treatment with VKA led to large expansions in hematoma volume and a poorer functional outcome (22, 23), whereas concentrations of dabigatran or rivaroxaban seen with clinical use of these agents did not increase hematoma volume (24, 25). A second murine model used highly focused laser beams to induce punctiform vascular lesions reminiscent of intracerebral micro-bleeds found in the human brain. In control animals the localised vascular lesions did not progress, whereas in mice pre-treated with a VKA, these small lesions led to macro-haemorrhages. In contrast, much like the control animals, mice treated with dabigatran did not develop macro-haemorrhages (25). Furthermore, pooled data from smaller trials with NOACs in patients with venous thromboembolism showed a similar 70 % relative risk reduction in intracranial bleeding. Gastro-intestinal bleeding NOACs may predispose to GI bleeding Given the reduction in all non-gi bleeding, it is surprising that the risk of GI bleeding is increased with three regimens and not reduced with the other two. A likely explanation lies in the variable amounts of active drug that accumulate in the GI tract, which has the potential to induce local bleeding. After being absorbed from the GI tract, VKAs target the hepatic enzyme, vitamin K epoxide reductase. In contrast, the NOACs directly target coagulation proteins and because they are incompletely absorbed by the GI tract, part of the oral dose remains in the lumen of the gut (26) ( Table 1). In contrast to VKAs, which can only cause GI bleeding via a systemic anticoagulant effect, NOACs have the potential to cause GI bleeding through their both systemic and local effects on the GI mucosa. Risk of GI bleeding differs among different NOAC regimens In contrast to the risk of ICH, which is consistently lower with NOACs compared with VKAs, the relative risk for GI bleeding varies considerably among different NOACs, from a lower relative risk with lower dose of edoxaban to a higher relative risk with rivaroxaban and high-dose dabigatran and edoxaban. As shown in Figure 1, the different effects on GI bleeding of Thrombosis and Haemostasis 112.5/2014 Schattauer 2014
4 Vanassche et al. Organ-specific bleeding patterns in anticoagulation 921 A B Figure 2: Anticoagulant effect of direct anticoagulants and VKA at low and high tissue factor levels. A) Left panel: Tissue factor (TF), released as a result of tissue damage, activates factor VII to factor VIIa, which results in the activation of factor X to Xa, and finally in the generation of active thrombin (IIa). Warfarin (mid panel) reduces the functional levels of the coagulation factors II, VII, IX and X. This reduces the rate of thrombin generation upon activation by TF. NOACs are direct inhibitors of either factor Xa (rivaroxaban, apixaban, edoxaban) or thrombin (dabigatran). The right panel illustrates the effect of thrombin inhibition by dabigatran. Each molecule of dabigatran (green) inhibits a single molecule of thrombin. B) Intense activation of coagulation by a high local concentration of tissue factor (TF) increases the thrombin generation (left panel). Compared to warfarin (mid panel), which reduces the rate of thrombin generation, the relative anticoagulant effect of dabigatran becomes smaller as large numbers of thrombin overwhelm the available dabigatran molecules. the NOACs are largely responsible for the differences in overall major bleeding. Although all NOACs are associated with a significant reduction in bleeding when GI bleeding is excluded ( Figure 1 B), the reduction in overall major bleeding is no longer statistically significant for dabigatran 150 mg and rivaroxaban because the risk of GI bleeding is increased with both regimens. Several factors might explain their different effects of NOACs on GI bleeding. Schattauer 2014 Thrombosis and Haemostasis 112.5/2014
5 922 Vanassche et al. Organ-specific bleeding patterns in anticoagulation Mechanism of GI bleeding with NOACs Differential absorption of NOACs The fraction of non-absorbed drug depends on the bio-availability of the NOAC, which varies from very low (dabigatran etexilate), to about % for edoxaban and rivaroxaban ( Table 1) (27 30). Dabigatran is administered as an inactive prodrug, dabigatran etexilate, which is converted to active dabigatran by esterases in the blood. However, the non-absorbed dabigatran etexilate is also converted into active metabolites in the GI tract, as evidenced by undetectable prodrug levels in contrast to high levels of the active drug in feces. Therefore, its formulation as an inactive pro-drug does not prevent accumulation of high local concentrations of active anticoagulant in the GI tract (28). It is not known where conversion from pro-drug to active drug occurs, but it is speculated that esterases in the gut bacterial flora are involved. This would explain why dabigatran is the only anticoagulant evaluated in the AF studies that has been reported to have a relatively higher ratio of lower GI bleeds compared to upper GI bleeds (31). Different dosing and relative anticoagulant intensity of NOACs Variation in the intensity of anticoagulation produced at the mucosal surface by different NOACs and different NOAC dosing regimens may also contribute to variation in GI bleeding risk. In the two studies that compared two doses of a NOAC with warfarin (5, 6), the incidence of GI bleeding was greatest with the higher than the lower dose of dabigatran and edoxaban, respectively. Furthermore, peak drug levels in the gut would be expected to be higher with a once-daily than a twice-daily dosing regimen, thereby explaining the relative increase in GI bleeding of rivaroxaban and high-dose edoxaban, compared to apixaban, which is administered twice daily. Differences in study populations An additional potential explanation for the observed differences in relative risk of GI bleeding among the NOACs may come from the differences between the patient populations included the trials. Patients in ENGAGE and ROCKET were slightly older than patients in RE-LY and ARISTOTLE and had higher mean CHADS2 scores (5 8). Older populations have a higher prevalence of asymptomatic GI mucosal lesions, which are more likely to bleed in the presence of high local anticoagulant levels. Indeed, in the apixaban trial, GI bleeding represented only 25 % of all major bleeding episodes in the control (VKA) arm, whereas in the rivaroxaban trial, GI bleeding accounted for 40 % of all major bleeds. Implications of organ-specific patterns of bleeding There are two main implications. First, ICH is associated with a very high mortality, and can result in major disability. The finding that NOACs consistently reduce ICH compared to VKAs may lower the threshold for prescribing anticoagulants, thus increasing the overall use of these potentially life-saving drugs in AF. Second, the increase in GI bleeding with three of the NOACs regimens has led to the evaluation in subsequent randomized trials of the use of concomitant treatment with proton pump inhibitors to reduce GI bleeding. Patients with known mucosal lesions prone to GI bleeding or a history of GI bleeding may benefit from lower doses of NOACs or selection of NOACs not associated with increased GI bleeding. A detailed report of bleeding subtypes, both in clinical trials, and in post-marketing registries or observational studies, should yield important further information on the impact of these organ-specific bleeding risks. Conclusion In the AF trials, compared to VKAs, NOACs reduced overall non- GI bleeding, markedly reduced ICH, but three regimens increased GI bleeding. We speculate that these patterns of bleeding might be explained by different pharmacological properties of the anticoagulants. NOACs inhibit single coagulation factors (Xa or IIa) in a stoichiometric manner. As a result, compared to VKAs, the effects of these anticoagulants can be readily overcome by TF-mediated activation of blood coagulation. Blood is exposed to TF at sites of vascular damage; the brain vasculature is particularly rich in TF. These observations could account for the reduction in overall non- GI bleeding and even larger reduction in ICH with NOACs compared to VKAs. The pattern of GI bleeding with certain NOACs can be explained by high levels of active drug within the GI tract, which could account for both the increase (3 NOAC regimens) and the variability (2 NOAC regimens similar, 1 NOAC regimen decreased) in the RR of GI bleeding compared to VKAs. Recognising these patterns of bleeding risk has important management implications, particularly for patients who are vulnerable to GI bleeding. Conflicts of interest John Eikelboom has received consulting fees and/or honoraria from Astra-Zeneca, Bayer, Boehringer-Ingelheim, BMS, Daiichi Sankyo, Eli Lilly, GSK, Pfizer, Janssen, Sanofi-Aventis and grants and/or in-kind support from Astra-Zeneca, Bayer, Boehringer- Ingelheim, BMS, GSK, Pfizer, Janssen and Sanofi-Aventis. None of the other authors declares any conflicts of interest. References 1. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: van Walraven C, Hart RG, Singer DE, et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. J Am Med Assoc 2002; 288: De Caterina R, Husted S, Wallentin L, et al. Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Thrombosis and Haemostasis 112.5/2014 Schattauer 2014
6 Vanassche et al. Organ-specific bleeding patterns in anticoagulation 923 Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease. Thromb Haemost 2013; 110: Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364: Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369: Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383: Wallentin L, Lopes RD, Hanna M, et al. Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation 2013; 127: Gallego P, Roldan V, Marin F, et al. Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation. Thromb Haemost 2013; 110: Wan Y, Heneghan C, Perera R, et al. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review. Circulation Cardiovasc Qual Outcom 2008; 1: Witt DM, Delate T, Hylek EM, et al. Effect of warfarin on intracranial haemorrhage incidence and fatal outcomes. Thrombosis Res 2013; 132: Piccini JP, Hellkamp AS, Lokhnygina Y, et al. Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trial. J Am Heart Assoc 2014; 3: e Gulati G, Hevelow M, George M, et al. International normalized ratio versus plasma levels of coagulation factors in patients on vitamin K antagonist therapy. Arch Pathol Lab Med 2011; 135: Dale B, Eikelboom JW, Weitz JI, et al. Dabigatran attenuates thrombin generation to a lesser extent than warfarin: could this explain their differential effects on intracranial haemorrhage and myocardial infarction? J Thrombosis Thrombol 2013; 35: Abbott NJ, Ronnback L, Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nature Rev Neurosci 2006; 7: Fisher MJ. Brain regulation of thrombosis and haemostasis: from theory to practice. Stroke 2013; 44: Poels MM, Vernooij MW, Ikram MA, et al. Prevalence and risk factors of cerebral microbleeds: an update of the Rotterdam scan study. Stroke 2010; 41 (10 Suppl): S103 S Lee SH, Ryu WS, Roh JK. Cerebral microbleeds are a risk factor for warfarin-related intracerebral haemorrhage. Neurology 2009; 72: Ueno H, Naka H, Ohshita T, et al. Association between cerebral microbleeds on T2*-weighted MR images and recurrent haemorrhagic stroke in patients treated with warfarin following ischemic stroke. Am J Neuroradiol 2008; 29: Foerch C, Arai K, Jin G, et al. Experimental model of warfarin-associated intracerebral haemorrhage. Stroke 2008; 39: Illanes S, Zhou W, Heiland S, et al. Kinetics of hematoma expansion in murine warfarin-associated intracerebral haemorrhage. Brain Res 2010; 1320: Lauer A, Cianchetti FA, Van Cott EM, et al. Anticoagulation with the oral direct thrombin inhibitor dabigatran does not enlarge hematoma volume in experimental intracerebral haemorrhage. Circulation 2011; 124: Lauer A, Pfeilschifter W, Schaffer CB, et al. Intracerebral haemorrhage associated with antithrombotic treatment: translational insights from experimental studies. Lancet Neurol 2013; 12: Desai J, Granger CB, Weitz JI, et al. Novel oral anticoagulants in gastroenterology practice. Gastrointest Endoscopy 2013; 78: Bathala MS, Masumoto H, Oguma T, et al. Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans. Drug Metabol Disp 2012; 40: Blech S, Ebner T, Ludwig-Schwellinger E, et al. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metabol Disp 2008; 36: Raghavan N, Frost CE, Yu Z, et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metabol Disp 2009; 37: Weinz C, Schwarz T, Kubitza D, et al. Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans. Drug Metabol Disp 2009; 37: Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011; 123: Schattauer 2014 Thrombosis and Haemostasis 112.5/2014
Chapter 1 Introduction
Chapter 1 Introduction There are several disorders which carry an increased risk of thrombosis, clots that interfere with normal circulation, including: venous thromboembolism (VTE), comprising both deep
More informationTrue/False: Idarucizumab can be utilized for the management of bleeding associated with dabigatran.
Discuss the role of idarucizumab for the management of bleeding associated with dabigatran Understand dosing, preparation and administration of idarucizumab I have no financial interest/arrangement or
More informationEfficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation
New Technologies, Diagnostic Tools and Drugs 981 Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation An indirect comparison
More informationDiscuss the role of idarucizumab for the management of bleeding associated with dabigatran
Discuss the role of idarucizumab for the management of bleeding associated with dabigatran Understand dosing, preparation and administration of idarucizumab I have no financial interest/arrangement or
More informationResults from RE-LY and RELY-ABLE
Results from RE-LY and RELY-ABLE Assessment of the safety and efficacy of dabigatran etexilate (Pradaxa ) in longterm stroke prevention EXECUTIVE SUMMARY Dabigatran etexilate (Pradaxa ) has shown a consistent
More informationNOAC trials for AF: A review
NOAC trials for AF: A review Chern-En Chiang, MD, PhD, FACC, FESC General Clinical Research Center Division of Cardiology Taipei Veterans General Hospital National Yang-Ming University Taipei, Taiwan Presenter
More informationIndications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute
Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute Disclosures Research Support/P.I. Employee Leo Pharma
More informationESC Congress 2012, Munich
ESC Congress 2012, Munich Anticoagulation in Atrial Fibrillation 2012: Which Anticoagulant for Which Patient? Stefan H. Hohnloser J.W. Goethe University Frankfurt am Main S.H.H. has served as a consultant,
More informationIs There a Role For Pharmacokinetic/ Pharmacodynamics Guided Dosing For Novel Anticoagulants? Christopher Granger
Is There a Role For Pharmacokinetic/ Pharmacodynamics Guided Dosing For Novel Anticoagulants? Christopher Granger 1 Disclosures Research contracts: Armetheon, AstraZeneca, Bayer, Boehringer Ingelheim,
More informationOld and New Anticoagulants For Stroke Prevention Benefits and Risks
Old and New Anticoagulants For Stroke Prevention Benefits and Risks September 15, 2014 Jonathan L. Halperin, M.D. The Cardiovascular Institute Mount Sinai Medical Center Disclosure Relationships with Industry
More informationCanadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC
Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC DEBATE: DOAC vs Good Old Warfarin André Roussin MD, FRCP, CSPQ CHUM and ICM/MHI Associate professor University of Montreal A. Roussin
More informationNew Aspects in the Diagnosis and Treatment of Atrial Fibrillation: Antithrombotic Therapy
New Aspects in the Diagnosis and Treatment of Atrial Fibrillation: Antithrombotic Therapy Hans-Christoph Diener Department of Neurology and Stroke Center University Hospital Essen Germany Conflict of Interest
More informationNeuroPI Case Study: Anticoagulant Therapy
Case: An 82-year-old man presents to the hospital following a transient episode of left visual field changes. His symptoms lasted 20 minutes and resolved spontaneously. He has a normal neurological examination
More informationIntroduction. 798 Theme Issue Article. New Oral Anticoagulants
798 Theme Issue Article New oral anticoagulants for stroke prevention in atrial fibrillation: impact of study design, double counting and unexpected findings on interpretation of study results and conclusions
More informationAtrial Fibrillation. Alan Bell, MD, CCFP. Staff Physician, Humber River Regional Hospital. University of Toronto
Pearls in Thrombosis 1 Atrial Fibrillation Alan Bell, MD, CCFP Staff Physician, Humber River Regional Hospital Assistant tprofessor, Department tof Family and Community Mdii Medicine University of Toronto
More informationControversies in Anticoagulation : Optimizing Outcome in NOACs for GI Bleeding Risk
Controversies in Anticoagulation : Optimizing Outcome in NOACs for GI Bleeding Risk Boyoung Joung, MD, PhD Professor, Division of Cardiology Director of Electrophysiology Laboratory Severance Cardiovascular
More informationPros and Cons of Individual Agents Based on Large Trial Results: RELY, ROCKET, ARISTOTLE, AVERROES
Pros and Cons of Individual Agents Based on Large Trial Results: RELY, ROCKET, ARISTOTLE, AVERROES Ralph L. Sacco, MS MD FAAN FAHA Olemberg Family Chair in Neurological Disorders Miller Professor of Neurology,
More informationAntithrombotics in the elderly. Robert Gabor Kiss FESC FACC Budapest
Antithrombotics in the elderly Robert Gabor Kiss FESC FACC Budapest The patient in the elderly You are sitting in Your office prescribing drugs and observing outcome The black box from prescription to
More informationAnti-thromboticthrombotic drugs
Atrial Fibrillation 2011: Anticoagulation strategies and clinical outcomes Panos E. Vardas President Elect of the ESC, Prof. of Cardiology, University Hospital of Crete Clinical outcomes affected by AF
More informationAntithrombotics in Stroke management
Antithrombotics in Stroke management Faculty: Robert Beveridge Relationships with commercial interests: Grants/Research Support: N/A Speakers Bureau/Honoraria: Astra Zeneca, Bayer, Boerhinger Ingelheim,
More informationESC Heart & Brain Workshop
Supported by Bayer, Bristol-Myers Squibb and Pfizer Alliance, Boehringer Ingelheim, Daiichi Sankyo Europe GmbH and Medtronic in the form of educational grants. The scientific programme has not been influenced
More informationIndividual Therapeutic Selection Of Anti-coagulants And Periprocedural. Miguel Valderrábano, MD
Individual Therapeutic Selection Of Anti-coagulants And Periprocedural Management Miguel Valderrábano, MD Outline Does the patient need anticoagulation? Review of clinical evidence for each anticoagulant
More informationDebate: New Generation Anti-Coagulation Agents are a Better Choice than Warfarin in the Management of AF
Debate: New Generation Anti-Coagulation Agents are a Better Choice than Warfarin in the Management of AF Bradley P. Knight, MD Director of Cardiac Electrophysiology Bluhm Cardiovascular Institute Northwestern
More informationA Patient Unsuitable for VKA Treatment
Will Apixaban change practice in atrial fibrillation? A Patient Unsuitable for VKA Treatment Professor Yoseph Rozenman The E. Wolfson Medical Center Jerusalem June 2013 Disclosures I have the following
More informationLessons from recent antithrombotic studies and trials in atrial fibrillation
Lessons from recent antithrombotic studies and trials in atrial fibrillation Thromboembolism cause of stroke in AF Lars Wallentin Uppsala Clinical Research Centre (UCR) Uppsala Disclosures for Lars Wallentin
More informationSecondary Preven-on of Thromboembolic Stroke: Clinical Data and Recommenda-ons from the ESC Atrial Fibrilla-on Guideline Update 2012
Secondary Preven-on of Thromboembolic Stroke: Clinical Data and Recommenda-ons from the ESC Atrial Fibrilla-on Guideline Update 2012 Professor Dan Atar Head, Dept. of Cardiology Councillor of the ESC,
More informationAnticoagulation Beyond Coumadin
Anticoagulation Beyond Coumadin Saturday, September 21, 2013 Crystal Mountain Resort and Spa Pratik Bhattacharya MD, MPH Stroke Neurologist, Michigan Stroke Network; Assistant Professor of Neurology; Wayne
More information2 Jean-Pierre Baeyens European Union Geriatric Medicine Society (EUGMS) representative
26 June 2014 Committee for Medicinal Products for Human Use (CHMP) Overview of comments received on 'Guideline on clinical investigation of medicinal products for prevention of stroke and systemic embolic
More informationcontroversies in anticoagulation: optimizing outcome for atrial fibrillation
controversies in anticoagulation: optimizing outcome for atrial fibrillation SUNDAY, NOVEMBER 13, 2016 WESTIN HOTEL NEW ORLEANS CANAL PLACE COLLABORATE INVESTIGATE EDUCATE PROVIDING PERSPECTIVE: CURRENT
More informationAnticoagulation: Novel Agents
Anticoagulation: Novel Agents Scott C. Woller, MD Medical Director, Anticoagulation Management, Intermountain Healthcare Central Region, co-director Venous Thromboembolism Program, Intermountain Medical
More informationClinical issues which drug for which patient
Anticoagulants - a matter of heart! Towards a bright future? Clinical issues which drug for which patient Sabine Eichinger Dept. of Medicine I Medical University of Vienna/Austria Conflicts of interest
More informationNadine Ajzenberg** Marie-Genevieve Huisse** Isabelle Mahé*** Edith Peynaud **** Aurelie Roche* Patricia Esselin* Laurence Auguste-Charlery*
«new oral anticoagulants and brain specificity» Claire Bal dit Sollier * Ariane Davout * Sun-Young Park* Irène Clavijo* Adeline-Zoe Thoux * Ioana Muller* Ludovic Drouet* Nadine Ajzenberg** Marie-Genevieve
More informationNOAC s across indications
Sektion CAMPUS INNENSTADT Med. Klinik und Poliklinik IV NOAC s across indications Ulrich Hoffmann, M.D. Division of Vascular Medicine University Hospital Munich, Germany Disclosure Speaker name: Ulrich
More informationOral Anticoagulants Update. Elizabeth Renner, PharmD, BCPS, BCACP, CACP Outpatient Cardiology and Anticoagulation
Oral Anticoagulants Update Elizabeth Renner, PharmD, BCPS, BCACP, CACP Outpatient Cardiology and Anticoagulation Objectives List the direct oral anticoagulant (DOAC) drugs currently available Describe
More informationStroke prevention, Clinical trials
Received: 13 May 2016 Revised: 8 August 2016 Accepted: 18 August 2016 DOI 10.1002/clc.22596 REVIEWS Special considerations for therapeutic choice of non vitamin K antagonist oral anticoagulants for Japanese
More informationINR as a Biomarker: Anticoagulation in Atrial Fib, Heart Failure, and Cardiovascular Disease Daniel Blanchard, MD, FACC, FAHA
INR as a Biomarker: Anticoagulation in Atrial Fib, Heart Failure, and Cardiovascular Disease Daniel Blanchard, MD, FACC, FAHA Professor of Medicine Director, Cardiology Fellowship Program Sulpizio Cardiovascular
More informationNOAs for stroke prevention in Atrial Fibrillation: potential advantages in the elderly patients. Giancarlo Agnelli
NOAs for stroke prevention in Atrial Fibrillation: potential advantages in the elderly patients Giancarlo Agnelli Internal & Cardiovascular Medicine - Stroke Unit University of Perugia, Italy My talk today
More informationOral Anticoagulation Drug Class Prior Authorization Protocol
Oral Anticoagulation Drug Class Prior Authorization Protocol Line of Business: Medicaid P & T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review
More informationStable CAD, Elective Stenting and AFib
Stable CAD, Elective Stenting and AFib Kurt Huber, MD, FESC, FACC, FAHA 3 rd Medical Department Cardiology & Intensive Care Medicine Wilhelminenhospital & Sigmund Freud Private University, Medical School
More informationIncidence and Impact of Antithrombotic-related Intracerebral Hemorrhage
Incidence and Impact of Antithrombotic-related Intracerebral Hemorrhage John J. Lewin III, PharmD, MBA, BCCCP, FASHP, FCCM, FNCS Division Director, Critical Care & Surgery Pharmacy Services, The Johns
More informationADC Slides for Presentation 02/10/2017
ADC 2017 Slides for Presentation ANTI THROMBOTIC THERAPY FOR NON VALVULAR ATRIAL FIBRILLATION IN PATIENTS WITH CHRONIC KIDNEY DISEASE: CURRENT VIEWS Martin A. Alpert, MD Brent M. Parker Professor of Medicine
More informationNew options in Stroke Prevention in AF Paul Dorian University of Toronto St Michael s Hospital
New options in Stroke Prevention in AF Paul Dorian University of Toronto St Michael s Hospital Disclosures: Honoraria, research support, and consulting f Sanofi, Boehringer-Ingleheim, Portola, BMS, Bayer,
More information6 th ACC-SHA Joint Meeting Jeddah, Saudi Arabia
6 th ACC-SHA Joint Meeting Jeddah, Saudi Arabia October 31 st - November 1 st, 2015 NOACS vs. Coumadin in Atrial Fibrillation: Is It Worth to Switch? Raed Sweidan, MD, FACC Consultant and Head of Cardiac
More informationNOAC 2015: What Have We Learned?
NOAC 2015: What Have We Learned? Milan Gupta, MD Canadian Cardiovascular Research Network University of Toronto, McMaster University www.ccrnmd.com Disclosures Honoraria / Research Grants Abbott, Aegerion
More informationThe Direct Oral Anticoagulants: Practical Considerations. David Garcia, MD University of Washington Seattle Cancer Care Alliance September 2015
The Direct Oral Anticoagulants: Practical Considerations David Garcia, MD University of Washington Seattle Cancer Care Alliance September 2015 Disclosure Occasional consultant to : BMS, Pfizer, Daiichi
More informationEvents after discontinuation of randomized treatment at the end of the ARISTOTLE trial
Events after discontinuation of randomized treatment at the end of the ARISTOTLE trial Christopher Granger, John Alexander, Michael Hanna, Jerry Wang, Puneet Mohan, Jack Lawrence, Elaine Hylek, Jack Ansell,
More informationPRACTICAL MANAGEMENT OF NOAC s December 8,
PRACTICAL MANAGEMENT OF NOAC s December 8, 2017 1 Faculty Disclosure Faculty: John Eikelboom MBBS, MSc, FRCPC Jack Hirsh/PHRI Chair in Thrombosis and Atherosclerosis Career Award, Heart and Stroke Foundation
More informationNovel Anticoagulants : Bleeding and Bridging
Novel Anticoagulants : Bleeding and Bridging Michael D. Ezekowitz, MBChB, DPhil, FACC, FAHA, FRCP, MA Professor, Thomas Jefferson Medical School Director Atrial Fibrillation Research and Education The
More informationNOACs Scegliere in Contesti Particolari
Gianluca Botto, FESC, FEHRA U.O.s. Elettrofisiologia ASST-Lariana, Como NOACs Scegliere in Contesti Particolari Presenter Disclosure Information Research support: Boston Scientific, Medtronic; St. Jude
More informationPeer Review Report #2. Novel oral anticoagulants. (1) Does the application adequately address the issue of the public health need for the medicine?
20 th Expert Committee on Selection and Use of Essential Medicines Peer Review Report #2 vel oral anticoagulants (1) Does the application adequately address the issue of the public health need for the
More informationAbstract. Introduction. imedpub Journals Doson Chua* Research Article. Cardiovascular Investigations: Open Access
Research Article imedpub Journals www.imedpub.com Cardiovascular Investigations: Open Access Vol. 2 No.1: 1 Use of Non-vitamin K Antagonist Oral Anticoagulants (NOAC) for Stroke Prevention in Patients
More informationAtrial fibrillation and anticoagulation JIR-PING BOEY, DEPARTMENT OF HAEMATOLOGY, FLINDERS MEDICAL CENTRE FEBRUARY 2016
1 Atrial fibrillation and anticoagulation JIR-PING BOEY, DEPARTMENT OF HAEMATOLOGY, FLINDERS MEDICAL CENTRE FEBRUARY 2016 Disclosures 2 No conflicts of interest Some questions 3 Should my patient with
More informationPatients presenting with acute stroke while on DOACs
Patients presenting with acute stroke while on DOACs Vemmos Kostas, MD, PhD Stroke Medicine Hellenic Cardiovascular Research Society Conflicts of interest Honoraria and speaker fees from: BAYER, SANOFI,
More informationAnticoagulation with Direct oral anticoagulants (DOACs) and advances in peri-procedural interruption of anticoagulation-- Bridging
Anticoagulation with Direct oral anticoagulants (DOACs) and advances in peri-procedural interruption of anticoagulation-- Bridging Scott C. Woller, MD Co-Director, Thrombosis Program Intermountain Medical
More informationLatest News and Clinical Applications of NOACs: What about Antidotes?
Optimizing outcomes in Atrial Fibrillation Latest News and Clinical Applications of NOACs: What about Antidotes? McMaster Cardiology Update September 11, 2015 Agenda Real world data on the use of NOACs
More informationNUOVI ANTICOAGULANTI NELL ANZIANO: indicazioni e controindicazioni. Mario Cavazza Medicina d Urgenza Pronto Soccorso AOU di Bologna
NUOVI ANTICOAGULANTI NELL ANZIANO: indicazioni e controindicazioni Mario Cavazza Medicina d Urgenza Pronto Soccorso AOU di Bologna Two major concerns Atrial Fibrillation: Epidemiology The No. 1 preventable
More informationDrug Class Monograph
Drug Class Monograph Class: Oral Anticoagulants Drug: Coumadin (warfarin), Eliquis (apixaban), Pradaxa (dabigatran), Savaysa (edoxaban), arelto (rivaroxaban) Formulary Medications: Eliquis (apixaban),
More informationMODULE 1: Stroke Prevention in Atrial Fibrillation Benjamin Bell, MD, FRCPC
MODULE 1: Stroke Prevention in Atrial Fibrillation Benjamin Bell, MD, FRCPC Specialty: General Internal Medicine Lecturer, Department of Medicine University of Toronto Staff Physician, General Internal
More informationDabigatran Evidence in Real Practice
ADVANCES IN CARDIAC ARRHYTHMIAS and GREAT INNOVATIONS IN CARDIOLOGY XXVII GIORNATE CARDIOLOGICHE TORINESI Torino, Centro Congressi Unione Industriale 23-24 Ottobre 2015 Dabigatran Evidence in Real Practice
More informationNOACs Update PD Dr. Jan Steffel Leitender Arzt, Klinik für Kardiologie Co-Leiter Rhythmologie Universitätsspital Zürich
NOACs Update 2016 PD Dr. Jan Steffel Leitender Arzt, Klinik für Kardiologie Co-Leiter Rhythmologie Universitätsspital Zürich Conflict of Interest Statement o o o o Consulting: Amgen, Astra Zeneca, AtriCure,
More informationAntithrombotic therapy in the ACS patient with atrial fibrillation
Antithrombotic therapy in the ACS patient with atrial fibrillation Kurt Huber, MD, FESC, FACC, FAHA 3 rd Medical Department Cardiology & Emergency Medicine Wilhelminenhospital Vienna, Austria Great Minds,
More informationRole of NOACs in AF Management. From Evidence to Real World Data Focus on Cardioversion
Role of NOACs in AF Management. From Evidence to Real World Data Focus on Cardioversion John Rickard MD, MPH Staff Electrophysiologist Cleveland Clinic Agenda NOACs: Update on Real World Data NOAC reversal:
More informationDirect Oral Anticoagulant Reversal
08 June 2018 No. 08 Direct Oral Anticoagulant Reversal M Khattab Moderator: E Hodgson School of Clinical Medicine Discipline of Anaesthesiology and Critical Care CONTENTS INTRODUCTION... 3 Pharmacokinetics
More informationAnticoagulation Task Force
Anticoagulation Task Force Newest Recommendations Donald Zabriskie, BPharm, MBA, RPh Pharmacy Patient Care Services Cleveland Clinic- Fairview Hospital THE DRUGS THE PERFECT ANTICOAGULANT Oral administration
More informationEngage AF-TIMI 48. Edoxaban in AF: What can we expect? Cardiology Update John Camm. St. George s University of London United Kingdom
Cardiology Update 2013 N S N O N H O H N S1 pocket Aryl binding N site O O N H N Cl Engage AF-TIMI 48 Edoxaban in AF: What can we expect? John Camm St. George s University of London United Kingdom Advisor
More informationANTITHROMBOTIC THERAPY IN CARDIOLOGY. Sokratis Pastromas, MD
HOSPITAL CHRONICLES 2012, VOLUME 7, SUPPLEMENT 1: 54 60 ANTITHROMBOTIC THERAPY IN CARDIOLOGY Newer Anticoagulants for Atrial Fibrillation: the Role of Dabigatran, Rivaroxaban, Apixaban and Edoxaban / RELY,
More informationAF stroke prevention in the Canadian context
AF stroke prevention in the Canadian context 5 th Annual State of the Heart Toronto, May 31, 2014 Andrew C.T. Ha, MD, MSc, FRCPC Cardiac Electrophysiology Toronto General Hospital, University Health Network
More informationDIRECT ORAL ANTICOAGULANTS
2017 Cardiovascular Symposium DIRECT ORAL ANTICOAGULANTS ERNESTO UMAÑA, MD, FACC ORAL ANTICOAGULANTS Vitamin K Antagonists (VKAs): Warfarin Non Vitamin K Antagonists Direct oral anticoagulants Novel Oral
More informationApixaban for stroke prevention in atrial fibrillation. August 2010
Apixaban for stroke prevention in atrial fibrillation August 2010 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationACCP Cardiology PRN Journal Club
ACCP Cardiology PRN Journal Club 1 Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation and Valvular Heart Disease Cody A. Carson, PharmD, BCPS PGY2 Cardiology Pharmacy Resident
More informationAndreas Clemens 1,2 *, Herbert Noack 3, Martina Brueckmann 3,4, Gregory Y. H. Lip 5. Abstract. Introduction
Twice- or Once-Daily Dosing of Novel Oral Anticoagulants for Stroke Prevention: A Fixed-Effects Meta-Analysis with Predefined Heterogeneity Quality Criteria Andreas Clemens 1,2 *, Herbert Noack 3, Martina
More informationDirect Oral Anticoagulants An Update
Oct. 26, 2017 Direct Oral Anticoagulants An Update Kathleen Heintz, DO, FACC Assistant Professor of Medicine Cooper Heart Institute Direct Oral Anticoagulants: DISCLAIMERS No Conflicts of Interest So what
More informationSTROKE PREVENTION 5/11/2015. Stroke Incidence by Age. Cardiogenic Embolism is the most common cause of stroke
(%) (%) 5/11/15 STROKE PREVENTION Stroke Incidence by Age T H E G E N E R A L P R A C T I C E E D U C A T I O N D A Y U N I V E R S I T Y O F Q U E E N S L A N D 3 1 O C T O B E R 2 1 5 A S S O C I A T
More informationAn indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation
476 Schattauer 2012 Review Article An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation Simon Mantha 1 ; Jack Ansell 2 1 Department of Medicine, Lahey Clinic, Burlington,
More informationRelationship between Center Time in Therapeutic Range and Comparative Treatment Effect of Rivaroxaban and Warfarin: Results from the ROCKET AF Trial
Relationship between Center Time in Therapeutic Range and Comparative Treatment Effect of Rivaroxaban and Warfarin: Results from the ROCKET AF Trial Jonathan P. Piccini, Frank Harrell, Yulia Lokhnygina,
More informationNOAC vs. Warfarin in AF Catheter Ablation
KHRS 2013 2013-Jun-15 NOAC vs. Warfarin in AF Catheter Ablation Jin-Seok Kim, MD Department of Cardiology Sejong General Hospital Bucheon, Republic of Korea Clinical Burden of AF Rhythm Disturbance Thromboembolic
More informationKCS Congress: Impact through collaboration
Stroke Prevention in Atrial Fibrillation (SPAF) in Kenya Elijah N. Ogola FACC University of Nairobi Kenya Cardiac Society Annual Scientific Congress Mombasa 28 th June 1 st July 2017 KCS Congress: Impact
More informationAntithrombotic Efficacy and Safety of Dabigatran Etexilate
130419 Luncheon Symposium_2013 춘계심장학회 Antithrombotic Efficacy and Safety of Dabigatran Etexilate Hui-Nam Pak, MD, PhD. Division of Cardiology Yonsei University Health System Atrial Fibrillation Risk of
More informationUS FDA Approves Pradaxa (dabigatran etexilate) a breakthrough treatment for stroke risk reduction in non-valvular atrial fibrillation
Press Release For non-us Healthcare Media Boehringer Ingelheim GmbH Corporate Communications US FDA Approves Pradaxa (dabigatran etexilate) a breakthrough treatment for stroke risk reduction in non-valvular
More informationFACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS
New Horizons In Atherothrombosis Treatment 2012 순환기춘계학술대회 FACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS Division of Cardiology, Jeonbuk National University Medical School Jei Keon Chae,
More informationContent 1. Relevance 2. Principles 3. Manangement
Intracranial haemorrhage and anticoagulation Department of Neurology,, Germany Department of Neurology, Heidelberg University Hospital, Germany Department of Clinical Medicine Copenhagen University, Denmark
More informationBlood Day for Primary Care
Blood Day for Primary Care including the Anticoagulation, use of novel oral anticoagulants in DVT/PE & atrial fibrillation Marc Carrier MD MSc. FRCPC Department of Internal Medicine, Division of Hematology,
More informationWhat s new with DOACs? Defining place in therapy for edoxaban &
What s new with DOACs? Defining place in therapy for edoxaban & Use of DOACs in cardioversion Caitlin M. Gibson, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy University of North Texas
More informationAnticoagulant therapy, coumadines or direct antithrombins
ATRIAL FIBRILLATION (AF) Anticoagulant therapy, coumadines or direct antithrombins Felicita Andreotti, MD PhD Aggregated Professor Dept of Cardiovascular Sciences, Catholic University, Rome, IT Consultant
More informationStarting or Resuming Anticoagulation or Antiplatelet Therapy after ICH: A Neurology Perspective
Starting or Resuming Anticoagulation or Antiplatelet Therapy after ICH: A Neurology Perspective Cathy Sila MD George M Humphrey II Professor and Vice Chair of Neurology Director, Comprehensive Stroke Center
More informationGLORIA -AF REGISTRY PROGRAMME
GLORIA -AF REGISTRY PROGRAMME EXECUTIVE SUMMARY The approval of novel oral anticoagulants has changed prescribing patterns for stroke prevention in atrial fibrillation (AF) worldwide. 1 There is a need
More informationPCI in Patients with AF Optimizing Oral Anticoagulation Regimen
PCI in Patients with AF Optimizing Oral Anticoagulation Regimen Walid I. Saliba, MD Director, Atrial Fibrillation Center Heart and Vascular Institute Cleveland Clinic 1 Epidemiology and AF and PCI AF and
More informationAtrial Fibrillation: Risk Stratification and Treatment New Cardiovascular Horizons St. Louis September 19, 2015
Atrial Fibrillation: Risk Stratification and Treatment New Cardiovascular Horizons St. Louis September 19, 2015 Christopher E. Bauer, MD, FACC, FHRS SSM Health Heart & Vascular Care Clinical Cardiac Electrophysiology
More informationNon Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Asian Patients With Nonvalvular Atrial Fibrillation Meta-Analysis
Non Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Asian Patients With Nonvalvular Atrial Fibrillation Meta-Analysis Kang-Ling Wang, MD; Gregory Y.H. Lip, MD; Shing-Jong Lin, MD, PhD;
More informationReversal Agents for NOACs (Novel Oral Anticoagulants)
Reversal Agents for NOACs (Novel Oral Anticoagulants) Current status and future challenges Paul A Reilly, PhD Clinical Research, Boehringer Ingelheim, Inc CSRC Symposium Washington DC Oct 18, 2016 Atrial
More informationCurrent state of the art and new horizons for stroke prevention in AF How to Improve Practical Decision-making in Everyday Clinical Practice
Current state of the art and new horizons for stroke prevention in AF How to Improve Practical Decision-making in Everyday Clinical Practice GREGORY Y H LIP MD FRCP (Lond Edin Glasg] FACC FESC Professor
More informationRETROSPECTIVE CLAIMS DATABASE STUDIES OF DIRECT ORAL ANTICOAGULANTS (DOACS) FOR STROKE PREVENTION IN NONVALVULAR ATRIAL FIBRILLATION
RETROSPECTIVE CLAIMS DATABASE STUDIES OF DIRECT ORAL ANTICOAGULANTS (DOACS) FOR STROKE PREVENTION IN NONVALVULAR ATRIAL FIBRILLATION Craig I. Coleman, PharmD Professor, University of Connecticut School
More informationPerioperative Management of Novel Oral Anticoagulants (NOACs) Hardy Shah PharmD NEANA March 2017
Perioperative Management of Novel Oral Anticoagulants (NOACs) Hardy Shah PharmD NEANA March 2017 Disclosures Presenter has no actual or potential conflicts of interest in relation to this program Question
More informationStroke Prevention in AF: How will it change in the next 5 years? Jeff Healey MD, MSc, FHRS Population Health Research Institute McMaster University
Stroke Prevention in AF: How will it change in the next 5 years? Jeff Healey MD, MSc, FHRS Population Health Research Institute McMaster University Disclosures Research Grants and speaking fees St. Jude
More informationPractical Considerations for Using Oral Anticoagulants in Patients with Chronic Kidney Disease
Practical Considerations for Using Oral Anticoagulants in Patients with Chronic Kidney Disease Cyrille K. Cornelio, Pharm.D. PGY2 Cardiology Pharmacy Resident The University of Oklahoma College of Pharmacy
More informationFibrillazione Atriale Non Valvolare: Come Orientare La Scelta Dei Nuovi Anticoagulanti Orali
Fibrillazione Atriale Non Valvolare: Come Orientare La Scelta Dei Nuovi Anticoagulanti Orali Gianluca Botto, MD, FAAC, FESC Divisione di Cardiologia Ospedale Sant Anna, Como The Promise of NOAs Antithrombotic
More informationAn Overview of Non Vitamin-K Antagonist Oral Anticoagulants. Helen Williams Consultant Pharmacist for CV Disease South London
An Overview of Non Vitamin-K Antagonist Oral Anticoagulants Helen Williams Consultant Pharmacist for CV Disease South London Contents Drugs and drug classes Licensed indications and NICE recommendations
More informationAtrial fibrillation. Causative factors of AF. Untreated/inadequately treated hypertension
Earn 3 CPD Points online Atrial fibrillation 30 years on Review of atrial fibrillation and the lessons of 30 years Professor Paul Dorian Division of Cardiology and Division of Clinical Pharmacology University
More informationWarfarin for Long-Term Anticoagulation. Disadvantages of Warfarin. Narrow Therapeutic Window. Warfarin vs. NOACs. Challenges Monitoring Warfarin
1 2:15 pm The Era of : Selecting the Best Approach to Treatment SPEAKER Gregory Piazza, MD, MS Presenter Disclosure Information The following relationships exist related to this presentation: Gregory Piazza,
More informationArrhythmias and Clinical EP Contemporary Management of Anticoagulant Therapies
Arrhythmias and Clinical EP Contemporary Management of Anticoagulant Therapies Samuel Asirvatham, MD & Ivan Mendoza, MD Saturday, June 24, 2017 11:15 a.m. to 12 p.m. Disclosures Relevant financial relationship(s)
More information